Ir para o conteúdo principal

BioNexus Gene Lab (NASDAQ: BGLC) — Perfil da empresa, notícias e dados financeiros

Logo de BioNexus Gene Lab
BGLC BioNexus Gene Lab
BioNexus Gene Lab   primary media
Perfil da empresa

BioNexus Gene Lab

BioNexus Gene Lab (NASDAQ: BGLC) is dedicated to pushing the boundaries of genetic research and biotechnological innovation. Specializing in cutting-edge genetic analysis and therapeutic development, BioNexus Gene Lab focuses on contributing to major advances in medicine and healthcare. Its operations span across various projects, including the development of personalized medicine, genetic editing technologies, and novel gene therapies aimed at treating complex diseases. The company has set its objectives towards creating sustainable solutions that address rare genetic disorders and enhance human health on a global scale. Through its rigorous research programs and collaborations with leading scientific institutions, BioNexus Gene Lab is committed to achieving breakthroughs that can transform lives and pave the way for a healthier tomorrow.

Resumo

Public USParticipação acionária
2017Ano de fundação
30Funcionários
Kuala Lumpur, MalaysiaSede
Carregando mapa...
Presença global

Operações

Todos os locais
Malaysia

Produtos e/ou serviços de BioNexus Gene Lab

  • Gene sequencing services offering comprehensive analysis for medical research and diagnostics.
  • Personalized genetic testing kits for disease risk assessment and personal health management.
  • Biopharmaceuticals development focusing on gene therapy for rare diseases.
  • Custom DNA synthesis for academic and industrial research purposes.
  • Genetic data storage solutions ensuring high security and easy accessibility for researchers.
  • Consultancy services providing expertise in genomics project design and data interpretation.

equipe executiva do BioNexus Gene Lab

  • Su-Leng TanCEO, President, Secretary & Director
  • Set Fui ChongChief Financial Officer
  • Kwan Wah ChanMarketing Manager
  • Too Kam ThamManaging Director

Principais indicadores financeiros

Resultados divulgados pela BioNexus Gene Lab , em USD.

Cap. de mercado
3,3 mi
Receita (TTM)
3,1 mi
P/L
—
LPA (diluído, TTM)
-1.3
Dividend yield
—
Margem de lucro
-82.4%
Receita e lucro anuais da BioNexus Gene Lab
Fim do ano fiscalReceitaResultado operacionalLucro líquido
7,4 mi-3,2 mi-3 mi
9,5 mi-1,6 mi-1,6 mi
9,8 mi-2,6 mi-2,6 mi
10,9 mi-291,2 mil-356 mil